Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery Cas9, dCas9-VPR Cell Lines

Horizon Discovery has released its stably expressing Cas9 and dCas9-VPR cell lines to aid researchers in gene knockout and gene activation experiments, respectively. The cell lines are optimized to work alongside Horizon's Edit-R predesigned synthetic single-guide RNA and CRISPRa guide RNA, for complete, simple, and streamlined CRISPR gene editing and modulation workflows.

The Cas9 and dCas9-VPR stable cell lines were generated using Horizon's Edit-R Lentiviral particles with a blasticidin resistance cassette, and are provided in pooled format. The cell lines are QC verified and validated to ensure stable expression and functionality of Cas9 or dCas9-VPR endonuclease in a range of common cell backgrounds, the company said. Both cell lines are available in the same background to enable loss- and gain-of-function studies to be performed in parallel. 

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.